US · AVBP · BIOTECHNOLOGY
ArriVent BioPharma, Inc. (AVBP) intrinsic value and stock valuation
$10.52as of 2026-11-21 · Mkt cap 1.44B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
ArriVent BioPharma, Inc. DCF and intrinsic value
InvestorsCraft values AVBP with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from AVBP’s statements →
ArriVent BioPharma, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2021–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating income | -$-177.53M | -$-94.31M | -$-74.59M | -$-36.91M | -$-8.7M |
| Net income | -$-166.31M | -$-80.49M | -$-69.33M | -$-36.91M | -$-51.61M |
| EPSd | -$-4.32M | -$-2.56M | -$-2.17M | -$-1.1M | -$-40.32M |
| Operating cash flow | -$-160.59M | -$-70.21M | -$-55.84M | -$-43.63M | -$-12.59M |
| Capital expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Free cash flow | -$-160.59M | -$-70.21M | -$-55.84M | -$-43.63M | -$-12.59M |
| Total assets | $333.2M | $274.9M | $163.1M | $182.8M | $43M |
| Total debt | $10K | $180K | $320K | $140K | $0.00 |
| Net debt | -$-45.53M | -$-74.12M | -$-150.07M | -$-163.23M | -$-37.28M |
| Total equity | $307.2M | $257.7M | $151.3M | $174.5M | $41.2M |
| Cash and short-term investments | $312.8M | $218.9M | $150.4M | $163.4M | $37.3M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Research and development expenses | $153.4M | $79M | $64.9M | $30.4M | $6.43M |
| Selling, general and administrative expenses | $24.2M | $15.3M | $9.71M | $6.47M | $2.26M |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $177.5M | $94.3M | $74.6M | $36.9M | $8.7M |
| Cost and expenses | $177.5M | $94.3M | $74.6M | $36.9M | $8.7M |
| Interest income | $11.2M | $13.8M | $5.26M | $0.00 | $0.00 |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $0.00 | $0.00 | $0.00 | $36.9M | $0.00 |
| Ebitda | -$-166.31M | -$-80.49M | -$-69.33M | $0.00 | -$-51.61M |
| Operating income | -$-177.53M | -$-94.31M | -$-74.59M | -$-36.91M | -$-8.7M |
| Total other income/expenses, net | $11.2M | $13.8M | $5.26M | $0.00 | -$-42.91M |
| Income before tax | -$-166.31M | -$-80.49M | -$-69.33M | -$-36.91M | -$-51.61M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-166.31M | -$-80.49M | -$-69.33M | -$-36.91M | -$-51.61M |
| Weighted average shares outstanding | $38.5M | $31.5M | $32M | $33.5M | $1.28M |
| Weighted average diluted shares outstanding | $38.5M | $31.5M | $32M | $33.5M | $1.28M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $312.8M | $218.9M | $150.4M | $163.4M | $37.3M |
| Net receivables | $60K | $500K | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $332.9M | $227M | $160M | $182.6M | $43M |
| Property, plant and equipment, net | $10K | $150K | $290K | $140K | $0.00 |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $47.7M | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $270K | $48M | $3.13M | $210K | $90K |
| Total assets | $333.2M | $274.9M | $163.1M | $182.8M | $43M |
| Accounts payable | $5.93M | $3.78M | $4.53M | $3.09M | $290K |
| Short-term debt | $10K | $160K | $140K | $130K | $0.00 |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $26M | $17.3M | $11.6M | $8.36M | $1.82M |
| Long-term debt | $0.00 | $10K | $180K | $10K | $0.00 |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $0.00 | $10K | $180K | $10K | $0.00 |
| Capital lease obligations | $10K | $180K | $320K | $140K | $0.00 |
| Total liabilities | $26M | $17.3M | $11.8M | $8.37M | $1.82M |
| Common stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Retained earnings | -$-404.64M | -$-238.33M | -$-157.84M | -$-88.51M | -$-51.61M |
| Accumulated other comprehensive income (loss) | $10K | -$-210K | $0.00 | $0.00 | -$0.00 |
| Total equity | $307.2M | $257.7M | $151.3M | $174.5M | $41.2M |
| Total investments | $267.3M | $192.3M | $0.00 | $0.00 | $0.00 |
| Total debt | $10K | $180K | $320K | $140K | $0.00 |
| Net debt | -$-45.53M | -$-74.12M | -$-150.07M | -$-163.23M | -$-37.28M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-166.31M | -$-80.49M | -$-69.33M | -$-36.91M | -$-51.61M |
| Depreciation and amortization | -$-3.03M | $0.00 | $0.00 | $0.00 | $0.00 |
| Stock-based compensation | $12.5M | $3.21M | $900K | $420K | $70K |
| Change in working capital | -$-3.77M | $7.07M | $12.6M | -$-7.15M | -$-3.94M |
| Accounts receivable | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | $2.14M | -$-750K | $1.38M | $2.8M | $290K |
| Net cash provided by operating activities | -$-160.59M | -$-70.21M | -$-55.84M | -$-43.63M | -$-12.59M |
| Investments in property, plant and equipment | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-71.23M | -$-192.47M | $0.00 | $0.00 | -$-40M |
| Common stock issued | $202.6M | $186M | $350K | $0.00 | $89.9M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $203.1M | $186.6M | $42.9M | $169.7M | $89.9M |
| Net change in cash | -$-28.75M | -$-76.1M | -$-12.98M | $126.1M | $37.3M |
| Cash at end of period | $45.5M | $74.3M | $150.4M | $163.4M | $37.3M |
| Operating cash flow | -$-160.59M | -$-70.21M | -$-55.84M | -$-43.63M | -$-12.59M |
| Capital expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Free cash flow | -$-160.59M | -$-70.21M | -$-55.84M | -$-43.63M | -$-12.59M |
Line items
Line items
Line items
About ArriVent BioPharma, Inc.
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
- CEO
- Zhengbin Yao
- Employees
- 77
- Beta
- 1.30
Explore
Frequently asked questions
What is the intrinsic value of ArriVent BioPharma, Inc. (AVBP)?
InvestorsCraft does not currently publish an intrinsic value for AVBP. How the IC value is calculated.
Is AVBP undervalued?
InvestorsCraft does not publish an undervaluation signal for AVBP at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.